A phase 2 clinical trial has demonstrated that pomalidomide, used to treat bone marrow cancer, is safe and effective for managing hereditary hemorrhagic telangiectasia, a rare genetic bleeding disorder. The results were published Sept. 18 in the New England Journal of Medicine.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
